Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared ...

Vepdegestrant significantly improved outcomes for certain patients with ER-positive, HER2-negative advanced breast cancer ...

Vepdegestrant, an oral PROTAC, nearly doubles progression-free survival in ESR1-mutated, ER-positive advanced breast cancer, ...

Sara M. Tolaney, MD, MPH, shares new data from the ASCENT-04 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer.

(RTTNews) - Arvinas Inc. (ARVN) and Pfizer Inc. (PFE) announced detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrog ...

Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Many patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

Breast cancer (BC) is the most prevalent cancer among women globally with two million diagnosed cases each year. Oestrogen ...